IP Library Granted Patent US 9,149,547
Granted Patent B2
US 9,149,547 · App. 13/890,912 · Granted Oct 6, 2015

Process for production of heterodimers of glutamic acid

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 9,149,547
App. No.
13/890,912
Granted
Oct 6, 2015
Kind
B2
Abstract

A manufacturing process for the preparation of radiolabeled compounds of formula (I) includes reacting compounds of formula (II) with a source of readionuclide of a halogen in the presence of an oxidant under acidic condition, wherein: *I is 123 I, 124 I, 125 I or 131 I; R is lower alkyl, optionally substituted with one or more fluorine atoms; Q is C(O), O, NR′, S, S(O) 2 , C(O) 2 , (CH 2 ) p ; Y is C(O), O, NR′, S, S(O) 2 , C(O) 2 , (CH 2 ) p ; R′ is H, C(O), S(O) 2 , C(O) 2 ; Z is H, C 1 -C 4 alkyl, benzyl, substituted benzyl or trialkylsilyl; m is 0, 1, 2, 3, 4 or 5; n is 0, 1, 2, 3, 4, 5 or 6; and p is 0, 1, 2, 3, 4, 5 or 6.

Claims (73)

1. A compound of formula (II):

wherein

R is lower alkyl, optionally substituted with one or more fluorine atoms;

Q is C(O), O, NR′, S, S(O) 2 , C(O) 2 , or (CH 2 ) p ;

Y is O, NR′, S, S(O) 2 , C(O) 2 , or (CH 2 ) p ;

or Q and Y together are —NR′C(O)NR′—;

R′ is H, C(O), S(O) 2 , or C(O) 2 ;

Z is H, C 1 -C 4 alkyl, benzyl, substituted benzyl or trialkylsilyl;

m is 1,2,3,4 or 5;

n is 0, 1, 2, 3, 4, 5 or 6; and

p is 2, 3, 4, 5 or 6.

2. The compound of claim 1 , wherein Y is O, NR′, C(O) 2 , (CH 2 ) p .

3. The compound of claim 1 , wherein Y is (CH 2 ) p and Q is NR′.

4. The compound of claim 1 , wherein R′ is H.

5. The compound of claim 1 , wherein Z is C 4 alkyl.

6. The compound of claim 1 , wherein Z is substituted benzyl.

7. The compound of claim 1 , wherein m is 4.

8. The compound of claim 1 , wherein n is 0.

9. The compound of claim 1 which is:

10. A stable composition comprising a radiolabeled compound of the formula (I)

and a pharmaceutically acceptable excipient under acidic conditions

wherein:

*I is 123 I, 124 I, 125 I, or 131 I;

R is lower alkyl, optionally substituted with one or more fluorine atoms;

Q is C(O), O, NR′, S, S(O) 2 , C(O) 2 , or (CH 2 ) p ;

Y is O, NR′, S, S(O) 2 , C(O) 2 , or (CH 2 ) p ;

or Q and Y together are —NR′C(O)NR′—;

R′ is H, C(O), S(O) 2 , or C(O) 2 ;

Z is H, C 1 -C 4 alkyl, benzyl, substituted benzyl or trialkylsilyl;

m is 1, 2, 3, 4 or 5;

n is 0, 1, 2, 3, 4, 5 or 6; and

p is 2, 3, 4, 5 or 6.

11. The stable composition of claim 10 , wherein Y is O, NR′, C(O) 2 , or (CH 2 ) p .

12. The stable composition of claim 10 , wherein Y is (CH 2 ) p and Q is NR′.

13. The stable composition of claim 10 , wherein R′ is H.

14. The stable composition of claim 10 , wherein Z is C 4 alkyl.

15. The stable composition of claim 10 , wherein Z is substituted benzyl.

16. The stable composition of claim 10 , wherein the pharmaceutically acceptable excipient comprises an ascorbate/ascorbic acid and a stabilizing amount of a gentisate stabilizer selected from gentisic acid and soluble, pharmaceutically acceptable salts thereof.

17. The stable composition of claim 16 , wherein the ascorbate/ascorbic acid is present at about 6% and the gentisate is present at about 3%.

18. The stable composition of claim 10 , wherein the acidic conditions have a pH from 4.5 to 5.5.

19. The stable composition of claim 10 having less than 5% free iodine.

20. The stable composition of claim 10 which is iodine-free.

21. A compound that is:

wherein:

R is lower alkyl, optionally substituted with one or more fluorine atoms; and

Z is H, C 1 -C 4 alkyl, benzyl, substituted benzyl or trialkylsilyl.

22. The compound of claim 21 , wherein Z is C 4 alkyl.

23. The compound of claim 21 , wherein Z is substituted benzyl.

24. A stable composition comprising a radiolabeled compound of the formula (I)

and a pharmaceutically acceptable excipient under acidic conditions;

wherein:

*I is 123 I, 124 I, 125 I, or 131 I;

R is lower alkyl, optionally substituted with one or more fluorine atoms;

Q is C(O), O, NR′, S, S(O) 2 , or C(O) 2 ;

Y is O, NR′, C(O)N(R′), S, S(O) 2 , C(O) 2 , or (CH 2 ) p ;

or Q and Y together are —NR′C(O)NR′—;

R′ is H, C(O), S(O) 2 , or C(O) 2 ;

Z is H, C 1 -C 4 alkyl, benzyl, substituted benzyl or trialkylsilyl;

m is 1, 2, 3, 4 or 5;

n is 0, 1, 2, 3, 4, 5 or 6 and p is 2, 3, 4, 5, or 6.

25. The stable composition of claim 24 , wherein the compound is:

and

a pharmaceutically acceptable excipient under acidic conditions

wherein:

Z is H, C 1 -C 4 alkyl, benzyl, substituted benzyl or trialkylsilyl, and

*I is 123 I, 124 I, 125 I, or 131 I.

26. The stable composition of claim 24 , wherein Z is C 4 alkyl.

27. The stable composition of claim 24 , wherein Z is substituted benzyl.

28. The stable composition of claim 24 , wherein the pharmaceutically acceptable excipient comprises an ascorbate/ascorbic acid and a stabilizing amount of a gentisate stabilizer selected from gentisic acid and soluble, pharmaceutically acceptable salts thereof.

29. The stable composition of claim 28 , wherein the ascorbate/ascorbic acid is present at about 6% and the gentisate is present at about 3%.

30. The stable composition of claim 24 , wherein the acidic conditions have a pH from 4.5 to 5.5.

31. The stable composition of claim 24 having less than 5% free iodine.

32. The stable composition of claim 24 which is iodine-free.

Assignments (3)
RELEASE OF SECURITY INTEREST Recorded Dec 2, 2022
From: WELLS FARGO BANK, N.A.
To: PROGENICS PHARMACEUTICALS, INC.; MOLECULAR INSIGHT PHARMACEUTICALS, INC.; PSMA DEVELOPMENT COMPANY, LLC
Reel/Frame 062047/0915 →
SECURITY INTEREST Recorded Dec 2, 2022
From: LANTHEUS MEDICAL IMAGING, INC.; MOLECULAR INSIGHT PHARMACEUTICALS, INC.; PSMA DEVELOPMENT COMPANY, LLC; PROGENICS PHARMACEUTICALS, INC.
To: CITIZENS BANK, N.A.
Reel/Frame 062047/0960 →
SECURITY AGREEMENT Recorded Aug 19, 2020
From: PROGENICS PHARMACEUTICALS, INC.; MOLECULAR INSIGHT PHARMACEUTICALS, INC.; PSMA DEVELOPMENT COMPANY LLC
To: WELLS FARGO BANK, N.A.
Reel/Frame 053538/0666 →